Company: ENTXW
Filing Date: 2025-01-10
Form Type: 424B5
Source: 0001178913-25-000079
Chunk: 0

Company: Entera Bio Ltd.
Filing Date: 2025-01-10
Form: 424B5
Chunk 0
---
Filed pursuant to Rule 424(b)(5) Registration No. 333-265286 Supplement No. 1 dated January 10, 2025 to Prospectus Supplement dated September 2, 2022
(to Prospectus dated June 9, 2022) Up to 30,000,000 Ordinary Shares This supplement no. 1 (this “Supplement”) supplements certain information contained in the prospectus supplement dated September 2, 2022 (as amended by this Supplement, the “prospectus supplement”) relating to the issuance and sale of our ordinary shares, par value NIS 0.0000769 per share (the “ordinary shares”), from time to time through Leerink Partners LLC (“Leerink Partners” or the “sales agent”) pursuant to a sales agreement (the “Sales Agreement”) with Leerink Partners, dated September 2, 2022. This Supplement should be read in conjunction with the prospectus supplement and the prospectus dated June 9, 2022 to which the prospectus supplement relates. Capitalized terms used in this Supplement and not defined herein have the respective meanings ascribed to such terms in the prospectus supplement. This Supplement amends and restates only those sections of the prospectus supplement contained in this Supplement; all other sections of the prospectus supplement remain unchanged. For clarity, references to “the prospectus supplement” or “this prospectus supplement” refer to the prospectus supplement as amended by this Supplement. This Supplement relates to the potential issuance and sale from time to time of up to an additional 30,000,000ordinary shares through Leerink Partners pursuant to the Sales Agreement. As of the date of this Supplement, out of 5,000,000 shares originally registered, we had sold 4,940,156 ordinary shares through Leerink Partners under the prospectus supplement and the accompanying prospectus for an aggregate gross sales price of approximately $10.1 million. Under this prospectus supplement, we may offer and sell from time to time up to an additional 30,000,000 ordinary shares through Leerink Partners under the Sales Agreement. Sales of our ordinary shares, if any, under this prospectus supplement will be made from time to time by any method deemed an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”). Leerink Partners is not required to sell any specific dollar amount or number of ordinary shares, but will act as